AdvisorNet Financial Inc Sells 3,880 Shares of Danaher Co. (NYSE:DHR)

AdvisorNet Financial Inc trimmed its position in Danaher Co. (NYSE:DHRGet Rating) by 64.8% in the second quarter, HoldingsChannel reports. The firm owned 2,110 shares of the conglomerate’s stock after selling 3,880 shares during the quarter. AdvisorNet Financial Inc’s holdings in Danaher were worth $535,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in Danaher by 2.1% in the 1st quarter. Vanguard Group Inc. now owns 51,004,840 shares of the conglomerate’s stock worth $14,961,250,000 after purchasing an additional 1,044,650 shares in the last quarter. Norges Bank bought a new stake in Danaher in the 4th quarter worth about $2,015,889,000. Parnassus Investments LLC grew its position in Danaher by 1.2% in the 1st quarter. Parnassus Investments LLC now owns 4,487,356 shares of the conglomerate’s stock worth $1,316,276,000 after purchasing an additional 55,114 shares in the last quarter. Fisher Asset Management LLC grew its position in Danaher by 3.7% in the 1st quarter. Fisher Asset Management LLC now owns 3,745,126 shares of the conglomerate’s stock worth $1,098,558,000 after purchasing an additional 132,703 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Danaher by 3.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,260,664 shares of the conglomerate’s stock worth $956,451,000 after purchasing an additional 108,414 shares in the last quarter. 77.27% of the stock is owned by institutional investors.

Analyst Ratings Changes

DHR has been the subject of a number of research reports. Cowen reduced their target price on shares of Danaher to $340.00 in a research report on Friday, July 22nd. Sanford C. Bernstein initiated coverage on shares of Danaher in a research report on Tuesday, August 16th. They set an “outperform” rating and a $340.00 target price for the company. Evercore ISI reduced their target price on shares of Danaher from $320.00 to $280.00 and set an “outperform” rating for the company in a research report on Tuesday, July 5th. Royal Bank of Canada increased their target price on shares of Danaher from $317.00 to $318.00 and gave the company an “outperform” rating in a research report on Friday. Finally, Robert W. Baird increased their target price on shares of Danaher from $319.00 to $325.00 in a research report on Friday, July 22nd. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $321.45.

Insiders Place Their Bets

In other Danaher news, CEO Rainer Blair sold 25,000 shares of the stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $300.00, for a total value of $7,500,000.00. Following the sale, the chief executive officer now directly owns 79,739 shares in the company, valued at approximately $23,921,700. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Walter G. Lohr sold 3,906 shares of the company’s stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $273.84, for a total value of $1,069,619.04. Following the completion of the transaction, the director now directly owns 12,115 shares in the company, valued at approximately $3,317,571.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Rainer Blair sold 25,000 shares of the firm’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $300.00, for a total value of $7,500,000.00. Following the transaction, the chief executive officer now directly owns 79,739 shares in the company, valued at $23,921,700. The disclosure for this sale can be found here. Insiders have sold 40,906 shares of company stock worth $11,823,179 in the last three months. 11.20% of the stock is currently owned by corporate insiders.

Danaher Stock Performance

Shares of DHR stock opened at $277.06 on Monday. Danaher Co. has a 12 month low of $233.71 and a 12 month high of $331.68. The company has a current ratio of 1.75, a quick ratio of 1.32 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $201.55 billion, a P/E ratio of 32.63, a PEG ratio of 1.33 and a beta of 0.88. The firm’s 50 day moving average is $279.57 and its 200 day moving average is $269.86.

Danaher (NYSE:DHRGet Rating) last posted its earnings results on Thursday, July 21st. The conglomerate reported $2.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.35 by $0.41. Danaher had a net margin of 20.61% and a return on equity of 18.57%. The business had revenue of $7.75 billion for the quarter, compared to analysts’ expectations of $7.29 billion. During the same period in the prior year, the company posted $2.46 EPS. The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Danaher Co. will post 10.4 earnings per share for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 28th. Shareholders of record on Friday, September 30th will be paid a $0.25 dividend. This represents a $1.00 annualized dividend and a yield of 0.36%. The ex-dividend date of this dividend is Thursday, September 29th. Danaher’s dividend payout ratio is presently 11.78%.

Danaher Company Profile

(Get Rating)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.

Recommended Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRGet Rating).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.